Alesta Therapeutics

Oral. Scalable. Precise. Designed for chronic conditions, where access and patient convenience matter most.

Alesta to Highlight ALE1 Clinical Progress at 44th Annual JP Morgan Healthcare Conference

Luc serves as a Managing Partner at Droia Ventures, a venture capital firm specializing in genetic diseases and oncology, with over €600 million under management. He represents Droia on the boards of Montis Biosciences, Vaderis, Volastra, Muna, Quralis, Vico Therapeutics, and Alesta.

Alesta combines expertise in chemistry and rare disease drug development with academic and industry leaders to advance innovation.

Alesta Therapeutics invites collaboration or partnerships.

Alesta Therapeutics is a biotech company developing novel oral small molecule therapies for underserved rare diseases.

BioMarin Pharmaceutical acquires Alesta Therapeutics for up to **$490 million**, targeting a single bone disease drug candidate from its pipeline. The deal focuses on Alesta’s rare disease therapeutic, which BioMarin will retain while divesting the rest of the portfolio. The acquisition expands BioMarin’s portfolio in rare bone disorders, leveraging Alesta’s specialized research.

Aug 2026Pharmaceutical TechnologyNews article

BioMarin Pharmaceutical acquires Alesta Therapeutics in a deal valued at up to **$490 million**, combining a **$275 million upfront payment** with potential **$215 million in development and regulatory milestones**. The transaction, approved by both boards, is set to close this quarter pending standard closing conditions. The acquisition expands BioMarin’s pipeline with Alesta’s therapeutic assets.

Aug 2026Leiden Bio Science ParkNews article

BioMarin Pharmaceutical acquires Alesta Therapeutics for **$275 million** to strengthen its rare bone disease portfolio. The deal expands BioMarin’s capabilities in treating rare skeletal disorders, directly competing with AstraZeneca in this niche market. Alesta’s expertise and pipeline assets are now integrated into BioMarin’s growing therapeutic offerings.

Aug 2026Fierce BiotechNews article

Alesta Therapeutics secures €65 million in Series A funding to develop oral small-molecule therapies for rare diseases. The round includes investors like Frazier Life Sciences, Droia Ventures, and Novartis Venture Fund. The company focuses on innovative treatments targeting underserved patient populations.

Jan 2025Droia Ventures – Investing in ImpactNews article